Ricks said reshoring manufacturing capacity for older essential medicines is “a valid thing,” adding that Eli Lilly is “happy ...

Eli Lilly said sales of weight loss drug Zepbound and diabetes treatment Mounjaro surged in the first quarter.

The Indianapolis-based drugmaker also reaffirmed its 2025 revenue guidance but noted that the calculation was based on existing tariff and trade policies.

In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against other Billionaire Ken Fisher’s healthcare stock picks with massive upside potential.

The last couple of quarters have been very favorable for Eli Lilly and Company (NYSE:LLY) and its position in the obesity and adjacent markets. The main competitor Novo Nordisk A/S (NVO ...

In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against other best long-term dividend stocks. Dividend stocks are increasingly popular with both every ...

Eli Lilly is scheduled to report its quarterly results on May 1. The company may report its Q1 results in line with peers. Don't face extreme market conditions unprepared. Get the professional ...

Pharmaceutical giant Eli Lilly and Co. sued Willow Health Services and three other companies in federal court in New Jersey and California, accusing them of selling unapproved compounded ...

Eli Lilly and Co., the maker of Zepbound and Mounjaro, announced success Thursday of its Phase 3 clinical trial for a once-daily GLP-1 pill — an oral form of the blockbuster medication used for ...

Eli Lilly (NYSE:LLY) and Co’s shares have recently marked a 52-week low, trading at $697.35, with a significant 10.6% decline just... (Reuters) -Primary care company knownwell said on Wednesday ...